The PERLA trial showed consistent OS benefits across various PD-L1 tumor proportion scores, favoring Jemperli over Keytruda.

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Padcev may be given alone or in combination with pembrolizumab (Keytruda). In Padcev clinical trials, the more common side effects differed depending on the treatment received. These are just a ...

Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at ...

Side effects were "generally manageable," according ... For comparison, the KEYNOTE-042 trial, which first established Keytruda monotherapy as the standard of care for PFD-L1-high NSCLC, showed ...

Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.

The study, which included a control arm receiving Keytruda, was stopped after it ... mainly due to “immune-mediated” side effects. That meant it was unlikely to show a statistically ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

We’ll begin in the world of biotherapeutics, where Werewolf Therapeutics is developing new immunotherapy drugs specifically designed to reduce the common and severe side effects often associated ...

Oncologists prescribe steroids to reduce chemotherapy side effects like fatigue and nausea ... These medications, including pembrolizumab (Keytruda) and nivolumab (Opdivo), are known to cause ...